STEP HFpEF DM EX9536-4773(NOVO NORDISK) Phase III May 2021- June 2022
Effect of Semaglutide 2.4 mg once-weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction, and type 2 diabetes. NCT04916470
STEP HFpEF EX9536-4665 (NOVO NORDISK) Phase III February 2021-March 2022
Effect of Semaglutide 2.4 mg once weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction. NCT04788511
AT-HOME HF PILOT SCP-01-008 (scPharmaceuticals, Inc.) Phase II February 2021-2022
Avoiding Treatment in the Hospital with Furoscix for the Management of Congestion in Heart Failure – A Pilot Study PRODUCT: Furoscix@ On-Body Infuser NCT04593823
ASPEN-COVID-19 AB201 (ARC Biopharma, Inc.) Phase IIb & III December 2020- January 2022
Assessing Safety, Hospitalization and Efficacy of rNAPc2in COVID-19Sequential randomized, multicenter, active comparator study to evaluate the hypothesis that rNAPc2 (AB201), a novel, potent and highly selective tissue factor inhibitor with anticoagulant, anti-inflammatory and potential antiviral properties, shortens time to recovery compared to heparin in hospitalized patients with COVID-19 and elevated D-dimer levels.
DARE-19 D1690C00081 (AstraZeneca) Phase III April 2020- June 2021
Dapagliflozin in Respiratory Failure in Patients With COVID-19 (DARE-19). This is an international, multicenter, parallel-group, randomized, double-blind, placebo controlled, study in hospitalized adult patients with COVID-19 in the US, Brazil, Mexico, Argentina, India, Canada, and UK. The study is evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily for 30 days in addition to background local standard of care therapy, on reducing complications and all-cause mortality, or improving clinical recovery. NCT04350593
DETERMINE–REDUCED D169EC00002 (AstraZeneca) Phase III April 2019 – Sept 2020
An International, multicenter, parallel-group, randomized, double-blind, placebo-controlled study evaluating Dapagliflozin on exercise capacity in Heart Failure patients with reduced Ejection Fraction. NCT03877224
CRD-733 CRF-733-104 (Cardurion Pharmaceuticals, LLC) Phase I Sept 2018-Oct 2019
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to evaluate the safety, tolerability, and pharmacokinetics of CRD-733 in patients with heart failure.
DELIVER D169CC00001 (AstraZeneca) Phase III August 2018 – February 2022
**First Site to Enroll a Patient in the United States.** An international, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF). NCT03619213
PRESERVED-HF D1690C00053(Saint Luke’s Hospital) Phase III Jan 2018- Completed 2021
Short term Clinical Trial Investigating the Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Diabetic or Pre-Diabetic Subjects with Preserved Ejection Fraction (HFpEF) Heart Failure. Qualification for Echocardiography sub-studies included.
DEFINE-HF D1690C00032 (Saint Luke’s Hospital) Phase III Jan 2018 – Completed 2019
A Randomized, Double-Bind, Placebo-Controlled Trial to Evaluate the Effects of Dapagliflozin on Heart Failure Disease-Specific Biomarkers (BNP and NTproBNP), Symptoms, Health Status, and Quality of Life in Patients with Chronic Heart Failure with Reduced Systolic Function (HFrEF). NCT02653482
DAPA-HF D1699C00001 (AstraZeneca) Phase III March 2016 – Completed 2019
A 1-3 year Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF). Qualification for Echocardiography Sub-Studies included. NCT04564742
THEMIS D513BC00001 (AstraZeneca) Phase III February 2014 – Completed 2019
A Multinational, Randomized, Double-Blind, Placebo-Controlled Phase IIIb Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus.
Eastern Shore Reseach Institute, LLC 